Search results for "Immunologic"

showing 10 items of 1115 documents

Clinical and anti-inflammatory effects of ultra-short preseasonal vaccine to Parietaria in asthma

2013

Objective: The ultra-short course preseasonal allergy vaccine, containing the adjuvant monophosphoryl lipid A (MPL), is effective in treating allergic symptoms; however, the efficacy in controlling asthmatics symptoms has not been fully demonstrated. We aimed at evaluating whether the ultra-short preseasonal course of immunotherapy contributes to asthma control. Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered, before the pollen season, to 20 Parietaria-sensitive mild, untreated asthmatics (M/F: 12/8; age: 38 ± 14 years). After the screening visit (visit 1), asthma control was assessed by the Asthma Control Test (ACT) immediately before the fi…

AdultMalePulmonary and Respiratory MedicineBreath TestParietariamedicine.drug_classmedicine.medical_treatmentMonophosphoryl Lipid Aairway inflammationSettore MED/10 - Malattie Dell'Apparato RespiratorioNitric OxideAnti-inflammatoryAllergic symptomsmedicineHumansPharmacology (medical)LungAsthmaInflammationVaccinesbiologybusiness.industryAllergy vaccineImmunotherapyMiddle Agedmedicine.diseasebiology.organism_classificationAsthmaParietariaquality of lifeBreath TestsDesensitization ImmunologicImmunologyFemaleimmunotherapybusinessVaccineAdjuvantHumanTherapeutic Advances in Respiratory Disease
researchProduct

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008

Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition. Objective To examine the benefits and risks of long-term treatment with danazol. Methods Data were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected b…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbdominal painPediatricsImmunologyDose-Response Relationship ImmunologicRisk AssessmentSeverity of Illness IndexEcallantideSeverity of illnessmedicineHumansImmunology and AllergyAdverse effectDepression (differential diagnoses)Retrospective StudiesDanazolbusiness.industryDanazolAngioedemas HereditaryEstrogen AntagonistsMiddle Agedmedicine.diseaseSurgeryDiscontinuationHereditary angioedemaFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugAnnals of Allergy, Asthma & Immunology
researchProduct

Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria

2010

Background Chronic spontaneous urticaria (CSU) lasting more than 6 weeks is one of the most disabling types of urticaria and often results in severely impaired quality of life. Patients with CSU are often unsatisfied with the standard treatment. Another treatment option recommended for patients with so-called nonresponding CSU according to the newest guidelines is intravenous immunoglobulin (IVIG). Objective To assess the efficacy and safety of high-dose IVIG as a treatment option in patients with therapy-resistant CSU. Methods Six patients with severe CSU unresponsive to other treatment options according to the newest guidelines for several weeks were treated with high-dose IVIG (2 g/kg ev…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentUrticariaImmunologyImmunoglobulin EQuality of lifeEdemaInternal medicineImmunopathologymedicineHumansImmunologic FactorsImmunology and AllergyAdverse effectAgedRetrospective Studiesbiologybusiness.industryStandard treatmentHeadacheImmunoglobulins IntravenousMiddle AgedSurgeryTreatment OutcomeBlood pressureChronic DiseaseHypertensionbiology.proteinItchingFemalemedicine.symptombusinessAnnals of Allergy, Asthma & Immunology
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn diseas…

2000

The pro-inflammatory cytokine interleukin (IL)-6 (refs. 1-5) can bind to cells lacking the IL-6 receptor (IL-6R) when it forms a complex with the soluble IL-6R (sIL-6R) (trans signaling). Here, we have assessed the contribution of this system to the increased resistance of mucosal T cells against apoptosis in Crohn disease (CD), a chronic inflammatory disease of the gastrointestinal tract. A neutralizing antibody against IL-6R suppressed established experimental colitis in various animal models of CD mediated by type 1 T-helper cells, by inducing apoptosis of lamina propria T cells. Similarly, specific neutralization of sIL-6R in vivo by a newly designed gp130-Fc fusion protein caused suppr…

AdultMaleSTAT3 Transcription FactorT-Lymphocytesmedicine.medical_treatmentT cellbcl-X ProteinApoptosisGeneral Biochemistry Genetics and Molecular BiologyMiceCrohn DiseaseAntigenAntigens CDCytokine Receptor gp130medicineAnimalsHumansInterleukin 6Mice Inbred BALB CMembrane GlycoproteinsbiologyInterleukin-6Models ImmunologicalInterleukinGeneral MedicineMiddle AgedReceptors Interleukin-6DNA-Binding ProteinsCytokinemedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ApoptosisImmunologyTrans-Activatorsbiology.proteinSTAT proteinCancer researchColitis UlcerativeFemaleSignal transductionProtein BindingSignal TransductionNature Medicine
researchProduct

Synovial fluid-derivedYersinia-reactive T cells responding to human 65-kDa heat-shock protein and heat-stressed antigen-presenting cells

1991

Humoral and cellular immune reactions to heat-shock proteins have been implicated in the pathogenesis of arthritis. Heat-shock proteins occur in bacteria as well as all eukaryotes and have been highly conserved during evolution. Cross-reactivity between bacterial and human heat-shock proteins induced at the site of inflammation may underlie the pathogenesis of some forms of arthritis. In order to test this hypothesis, we raised and cloned a Yersinia-specific T cell line from the synovial fluid lymphocytes of a patient with Yersinia-induced reactive arthritis. From this line we obtained a CD4+ T cell clone that proliferated in response to Yersinia antigens and both to the mycobacterial and t…

AdultMaleSalmonella typhimuriumHot TemperatureT-LymphocytesT cellImmunologyDose-Response Relationship ImmunologicAntigen-Presenting CellsArthritisCross ReactionsBiologyArthritis ReactiveImmune systemTetanus ToxinAntigenHeat shock proteinCandida albicansSynovial FluidEscherichia colimedicineHumansImmunology and AllergySynovial fluidAntigen-presenting cellHeat-Shock ProteinsT lymphocytebeta-Galactosidasemedicine.diseaseYersiniaCell biologymedicine.anatomical_structureImmunologyEuropean Journal of Immunology
researchProduct

Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura – haemolytic uraemic syndrome

2010

AdultMaleSalvage TherapyAdolescentPurpura Thrombotic ThrombocytopenicADAMTS13 ProteinCase ReportMiddle AgedADAM ProteinsAntibodies Monoclonal Murine-DerivedTreatment OutcomeHumansImmunologic FactorsFemaleRituximabrefractory thrombotic thrombocytopenic purpura
researchProduct

Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.

2017

Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in …

AdultMaleSevere asthmaAllergyAllergen immunotherapymedicine.medical_specialtyEfficacyCost-effectiveness.Cost effectivenessImmunologyMEDLINEAtopy03 medical and health sciences0302 clinical medicineHypersensitivityAdultsImmunology and AllergyMedicineHumansIntensive care medicineChildChildrenAllergen immunotherapyAsthmabusiness.industryAsthma treatmentAllergensmedicine.diseaseAsthmaClinical trialSystematic review030228 respiratory systemDesensitization ImmunologicSLIT030220 oncology & carcinogenesisImmunologyFemaleSafetySCITbusinessJournal of investigational allergologyclinical immunology
researchProduct

The human hepatic asialoglycoprotein receptor is a target antigen for liver-infiltrating T cells in autoimmune chronic active hepatitis and primary b…

1990

Autoantibodies to the human hepatic asialoglycoprotein receptor have been found in nearly 50% of the sera of patients with autoimmune chronic active hepatitis and in 15% of patients with primary biliary cirrhosis. In this study we demonstrate that the human hepatic asialoglycoprotein receptor is also a target antigen for T cell-mediated immune responses. Peripheral blood lymphocytes of 37% (7 of 19) of patients with autoimmune chronic active hepatitis and 33% (2 of 6) of patients with primary biliary cirrhosis showed a proliferative response to highly purified human hepatic asialoglycoprotein receptor, whereas no proliferation was found with peripheral blood lymphocytes of patients with chr…

AdultMaleT-LymphocytesAsialoglycoprotein ReceptorLymphocyte Activationdigestive systemAutoantigensAutoimmune DiseasesPrimary biliary cirrhosisAntigenmedicineHumansHepatic Asialoglycoprotein ReceptorReceptors ImmunologicHepatitis ChronicHepatitisAutoimmune diseaseHepatologymedicine.diagnostic_testbusiness.industryLiver Cirrhosis BiliaryHLA-DR AntigensMiddle Agedmedicine.diseaseLiverLiver biopsyImmunologyAsialoglycoprotein receptorbusinessViral hepatitisHepatology (Baltimore, Md.)
researchProduct

The Italian Multiple Sclerosis Database Network (MSDN): The risk of worsening according to IFNβ exposure in multiple sclerosis

2006

We evaluated the risk of worsening according to the length of exposure to interferon beta (IFNβ)ina large cohort of 2090 multiple sclerosis patients collected by the Italian MS Database Network. Overall 44-140 patient-visits with a follow-up of 22-143 patient-years were evaluated. Forty-one per cent of patients were exposed to IFNβ for up to 2 years, 39% for 2- 4 years and 20% for more than 4 years. A Cox regression model was used to analyse two clinical outcomes: disability progression and worsening of relapse rate. The technique of propensity score was applied to reduce bias in the comparison of non-randomized groups. The risks of disability progression (HR=0.23; 95% CI: 0.17 - 0.30) and …

AdultMaleTime Factorscomputer.software_genreCentral nervous system diseaseCohort Studies03 medical and health sciencesDisability Evaluation0302 clinical medicineAdjuvants ImmunologicmedicineHumansImmunologic Factors030212 general & internal medicineRisk factorMULTIPLE SCLEROSISDemographyProportional Hazards ModelsRISKAnalysis of VarianceDatabasebusiness.industryProportional hazards modelMultiple sclerosisInterferon-betaIFNP; Long term effectiveness; Multiple sclerosis; Observational studies;Middle Agedmedicine.diseaseTreatment OutcomeNeurologyDatabases as TopicItalyPropensity score matchingDisease ProgressionRegression AnalysisObservational studyFemaleNeurology (clinical)Analysis of variancebusinesscomputer030217 neurology & neurosurgeryCohort study
researchProduct